Eli Lilly plans to invest in challenging areas such as Alzheimer's disease, ALS, addiction, chronic pain and gene therapy, utilizing the financial success from its GLP-1 drugs. "We see that as an obligation to invest in some of these big problems that are hiding in plain sight, to try and make a difference for the health of your community," said Eli Lilly's Chief Scientific Officer Dan Skovronsky.